{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:54:37Z","timestamp":1762505677397},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.ygyno.2010.10.028","type":"journal-article","created":{"date-parts":[[2010,11,15]],"date-time":"2010-11-15T09:10:39Z","timestamp":1289812239000},"page":"205-208","source":"Crossref","is-referenced-by-count":8,"title":["Ovarian cancer patient surveillance after curative-intent initial treatment"],"prefix":"10.1016","volume":"120","author":[{"given":"Garo Z.","family":"Harmandayan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine S.","family":"Virgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall K.","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2010.10.028_bb0005","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0010","series-title":"Principles and Practice of Gynecologic Oncology","first-page":"895","article-title":"Epithelial Ovarian Cancer","author":"Ozols","year":"2005"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0015","series-title":"Cancer Patient Follow-Up","first-page":"336","article-title":"Ovarian Carcinoma","author":"Perez","year":"1997"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1200\/JCO.1989.7.2.223","article-title":"Ten-year follow-up of patients receiving cisplatin, doxorubicin and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma","volume":"7","author":"Sutton","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0025","first-page":"293","article-title":"NCCN Ovarian Cancer Practice Guidelines, The National Comprehensive Cancer Network","volume":"10","author":"Morgan","year":"1996","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0030","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.1995.03520300065039","article-title":"NIH Consensus Development Panel on Ovarian Cancer: Ovarian cancer: screening, treatment, and follow-up","volume":"273","author":"Seltzer","year":"1995","journal-title":"JAMA"},{"issue":"suppl. 2","key":"10.1016\/j.ygyno.2010.10.028_bb0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/annonc\/mdn073","article-title":"ESMO Guidelines Working Group. Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"19","author":"Aebi","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0040","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1525-1438.2006.00421.x","article-title":"Routine follow-up after treatment for a gynecological cancer: a survey or practice","volume":"16","author":"Kew","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0045","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejogrb.2003.10.029","article-title":"Posttherapy surveillance and aftercare in ovarian cancer","volume":"114","author":"von Georgi","year":"2004","journal-title":"Eur J Obstet Gyn"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0050","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1200\/JCO.2009.23.0250","article-title":"Physician referral for fertility preservation in oncology patients: a national study of practice behaviors","volume":"27","author":"Quinn","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0055","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0093-7754(03)00100-3","article-title":"The follow-up of ovarian cancer","volume":"30","author":"Vaidya","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0060","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1525-1438.2007.00826.x","article-title":"Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature","volume":"17","author":"Gadducci","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0065","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0090-8258(92)90216-6","article-title":"Clinical surveillance of gynecologic cancer patients","volume":"46","author":"Barnhill","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0070","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1479-828X.1995.tb01986.x","article-title":"Follow-up of patients with gynaecological cancer","volume":"35","author":"Kerr-Wilson","year":"1995","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2006.10.060","article-title":"Clinical use of combined positron emission tomography and computed tomography (FDG-PET\/CT) in recurrent ovarian cancer","volume":"105","author":"Thrall","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ygyno.2006.03.004","article-title":"The impact of PET\/CT in the management of recurrent ovarian cancer","volume":"103","author":"Simcock","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0085","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1067\/mob.2002.125888","article-title":"Evaluation of beta 1, 4- galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer","volume":"187","author":"Odunsi","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0090","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2008.04.030","article-title":"The role of regular physical examination in the detection of ovarian cancer recurrence","volume":"110","author":"Chan","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.critrevonc.2008.12.008","article-title":"Surveillance of patients after initial treatment of ovarian cancer","volume":"71","author":"Gadducci","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/003655102317475434","article-title":"Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up","volume":"62","author":"Tuxen","year":"2002","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0105","first-page":"135","article-title":"Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer","volume":"8","author":"Crombach","year":"1985","journal-title":"Cancer Detect Prev"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0110","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/jco.2009.27.18_suppl.1","article-title":"A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA 125 level alone versus delayed treatment based on conventional clinical indicators","volume":"27","author":"Rustin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0115","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/IGC.0b013e3181a1cc02","article-title":"Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: A retrospective Italian multicentric study","volume":"19","author":"Gadducci","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.seminoncol.2008.12.003","article-title":"Management of recurrent ovarian carcinoma: current status and future directions","volume":"36","author":"Martin","year":"2009","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0125","first-page":"1583","article-title":"Impact of follow-up testing on survival and quality of life in breast cancer patients: a multicenter randomized controlled trial","volume":"271","author":"The GIVIO investigators","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0130","doi-asserted-by":"crossref","DOI":"10.1001\/jama.1994.03510440053032","article-title":"Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial","volume":"271","author":"Del Turco","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0135","series-title":"Cancer Patient Follow-Up","author":"Johnson","year":"1997"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0140","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.1995.03520470045030","article-title":"Cost of patient follow-up after potentially curative colorectal cancer treatment","volume":"273","author":"Virgo","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2010.10.028_bb0145","series-title":"To err is human: building a safer health system","author":"Kohn","year":"2000"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810007742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810007742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T20:40:11Z","timestamp":1592080811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825810007742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0090825810007742"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.10.028","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}